Back to Search Start Over

Isolated mangiferin and naringenin exert antidiabetic effect via PPAR γ /GLUT4 dual agonistic action with strong metabolic regulation

Authors :
Atul Rawat
Amit Rai
Biswanath Maity
Pranesh Kumar
Bolay Bhattacharya
Amit K Keshari
Vinit Raj
Sudipta Saha
Anand Prakash
Arnab De
Amalesh Samanta
Dinesh Kumar
Ashok K. Singh
Source :
Chemico-Biological Interactions. 280:33-44
Publication Year :
2018
Publisher :
Elsevier BV, 2018.

Abstract

In this study, we isolated two compounds from the leaves of Salacia oblonga (SA1, mangiferin and SA2, naringenin), and their structures were confirmed by infrared spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry. SA1 and SA2 were orally administered to streptozotocin-induced diabetic rats at 50 and 100 mg/kg daily for 15 days. Blood glucose level, serum lipid profile, oxidative stress parameters, histopathology, docking, molecular parameters, and NMR-based metabolic perturbation studies were performed to investigate the pharmacological activities of SA1 and SA2. Results suggested that both compounds reduced blood glucose level, restored body weight, and normalized lipid concentrations in the serum and oxidative stress biomarkers in the liver and pancreas. In addition, the docking study on several diabetes-associated targets revealed that both compounds had a strong binding affinity towards peroxisome proliferator-activated receptor gamma (PPARγ) and glucose transporter type 4 (GLUT4). Further real-time reverse transcription polymerase chain reaction and western blot analyses were performed to confirm the gene and protein expression levels of PPARγ and GLUT4 in the pancreatic tissues. Data obtained from the molecular studies showed that both compounds exhibited antidiabetic effects through dual activation of PPARγ/GLUT4 signaling pathways. Finally, the NMR-based metabolic studies showed that both compounds normalized the diabetogenic metabolites in the serum. Altogether, we concluded that SA1 and SA2 might be potential antidiabetic lead compounds for future drug development.

Details

ISSN :
00092797
Volume :
280
Database :
OpenAIRE
Journal :
Chemico-Biological Interactions
Accession number :
edsair.doi...........2d24adf6c479fe154869ae500e255057
Full Text :
https://doi.org/10.1016/j.cbi.2017.12.007